IGF-1 LR3

Overview

IGF-1 LR3 (Long Arginine-3 IGF-1) is a synthetic analog of insulin-like growth factor 1 modified to escape sequestration by IGF-binding proteins (IGFBPs). The N-terminal extension and Arg3 substitution dramatically reduce IGFBP-1, -3, and -5 binding, leaving more free IGF-1 in circulation and extending the functional half-life from minutes (native IGF-1) to ~20–30 hours. Originally developed as a research-grade tool for cell-culture work — and still primarily used for that purpose in legitimate science — it became a widely-circulated bodybuilding peptide claimed to drive hyperplastic muscle growth. Human clinical-trial evidence for body composition, strength, or healing in athletic populations is essentially absent. The risk profile, by contrast, is characterized: hypoglycemia from insulin-receptor cross-activation, theoretical (and oncologically relevant) sustained mitogenic signaling in any IGF-1R-expressing tissue, and the chronic-IGF-1-elevation safety concerns that apply to GH-secretagogue stacks at scale. Hold the line: the evidence is thin, the risks are real, and community framing is not evidence.

Mechanism

Agonist at the IGF-1 receptor (IGF-1R), driving anabolic and mitogenic signaling via PI3K/AKT and MAPK pathways. Cross-activates the insulin receptor at higher doses, producing hypoglycemia. Reduced IGFBP binding means a much larger free fraction reaches tissues, extending biological activity well beyond what native IGF-1 can achieve. Mitogenic at any IGF-1R-expressing tissue — relevant to both desired (muscle) and undesired (any pre-existing or occult tumor) effects.

Evidence by indication

We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.

Studied dose ranges

The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.

Contraindications

• Active or suspected malignancy (pre-existing cancer or strong family/personal cancer history) — IGF-1R agonism is mitogenic and should be considered contraindicated in this context
• Diabetes — IGF-1 LR3 cross-activates the insulin receptor and substantially increases hypoglycemia risk
• Pregnancy and breastfeeding
• Adolescents with open growth plates (use only under endocrinology supervision; recombinant IGF-1 in pediatric growth disorders is the appropriate context, not LR3)
• Concurrent use with insulin or insulin secretagogues without close glycemic monitoring
• Hypersensitivity to peptide formulations

Reported side effects

• Hypoglycemia (potentially severe; can occur acutely after injection — community guidance to consume carbohydrate post-injection is well-known but not safe at scale)
• Hypoglycemia-driven sympathetic symptoms: tremor, sweating, tachycardia, anxiety
• Joint pain, jaw discomfort with chronic use (consistent with IGF-1 effects on growth tissue)
• Gynecomastia, fluid retention, edema
• Headache
• Theoretical / unstudied long-term: any IGF-1R-driven tumor growth promotion in pre-existing or occult malignancies
• Long-term safety in non-deficiency populations is unstudied

Reconstitution & storage

Lyophilized powder reconstituted with bacteriostatic water (some vendors recommend acetic-acid buffer for stability, particularly for native IGF-1; LR3 is more stable in plain BAC water). A 1 mg vial in 1 mL BAC water = 1000 mcg/mL, making a 50 mcg dose = 5 units on a U-100 syringe. Use the Juno calculator to verify. Identity and purity of research-vendor product vary widely.

Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 14–30 days (somewhat shorter than typical peptide stability windows).

Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.

Editorial note

DRAFT — pending Wayne's review. IGF-1 LR3 is one of the highest risk-to-evidence-ratio entries in this batch. Hypoglycemia from insulin-receptor cross-activity is acute and clinically meaningful; the theoretical oncologic concerns from chronic IGF-1R stimulation are real even if formally unproven. There is essentially zero human clinical-trial evidence for body composition or healing in athletic populations. Hold at Tier 3 with strong safety framing; the recombinant native-IGF-1 (mecasermin) Tier 1 evidence does NOT propagate to LR3 and the entry must say so clearly. This is the kind of entry that protects users from worse choices.

Citations

1. [1]

   Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity

   Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. · Journal of Clinical Endocrinology & Metabolism · 2007 · PMID 17389701

   Reference for the related FDA-approved drug mecasermin (recombinant native IGF-1) — included to anchor the regulatory/indication distinction from LR3.

   View source
2. [2]

   Insulin-like growth factor (IGF)-I and analogues with low affinity for IGF-binding proteins display enhanced biological activity in vivo

   Francis GL, Aplin SE, Milner SJ, McNeil KA, Ballard FJ, Wallace JC. · Biochemical Journal · 1992 · PMID 1311434

   Foundational pharmacology characterizing reduced-IGFBP-binding IGF-1 analogs (the LR3 family); the original cell-biology rationale.

   View source